This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Armisarte (previously ...
Human medicines European public assessment report (EPAR): Pluvicto, lutetium (17...
Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, ...
Consolidated 3-year work plan for the Emergency Task Force (ETF)
Minutes of the COMP meeting 3-5 December 2024
Human medicines European public assessment report (EPAR): Korjuny, catumaxomab, ...
Human medicines European public assessment report (EPAR): Hetronifly, serplulima...
Agenda of the CVMP meeting 11-13 February 2025
Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, D...
Jakavi-H-C-002464-X-0070-G : EPAR - Assessment report - Variation
Human medicines European public assessment report (EPAR): Blincyto, blinatumomab...
Applications for new human medicines under evaluation: February 2025
Pharmacovigilance Risk Assessment Committee (PRAC): 10 - 13 February 2025, Europ...
Agenda of the PRAC meeting 10-13 February 2025
Human medicines European public assessment report (EPAR): Ituxredi, rituximab, D...
Methylphenidate, prolonged-release tablet 18 mg, 27 mg, 36 mg and 54 mg and modi...
List of signals discussed at PRAC since September 2012
Members of the Coordinating group of European network of paediatric research at ...
Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, ...
Pharmacovigilance Risk Assessment Committee (PRAC): 25 - 28 November 2024, Europ...
Minutes of the PRAC meeting 25-28 November 2024